AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
foslevodopa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors | 5726 | 97321-87-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Foslevodopa and foscarbidopa combination (ABBV-951) was aproved by PMDA for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa, respectively. They have higher solubility than their parent compounds, which allows them to be administered as a continuous subcutaneous infusion.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BMX,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 69 | |||
| kinase-selectivity-class | ACVR2B,AURKA,AURKB,AXL,BMX,BRAF,CDK1,CDK4,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,IKBKB,IRAK3,JAK2,MAP2K6,MAP3K14,MAPK7,MAPK8,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 31 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 23, 2022 | PMDA | AbbVie GK |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N04BA07 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopa and dopa derivatives |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:50266 | prodrug |
Related Drugs by ATC class:
N04BA Dopa and dopa derivatives 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Parkinson's disease | indication | 49049000 | DOID:14330 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) | VYALEV | ABBVIE | N216962 | Oct. 16, 2024 | RX | SOLUTION | SUBCUTANEOUS | 10174061 | Oct. 21, 2035 | TREATMENT OF MOTOR FLUCTUATIONS IN ADULTS WITH ADVANCED PARKINSONS DISEASE |
| 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) | VYALEV | ABBVIE | N216962 | Oct. 16, 2024 | RX | SOLUTION | SUBCUTANEOUS | 9446059 | Oct. 21, 2035 | TREATMENT OF MOTOR FLUCTUATIONS IN ADULTS WITH ADVANCED PARKINSONS DISEASE |
| 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) | VYALEV | ABBVIE | N216962 | Oct. 16, 2024 | RX | SOLUTION | SUBCUTANEOUS | 12251365 | June 10, 2040 | TREATMENT OF MOTOR FLUCTUATIONS IN ADULTS WITH ADVANCED PARKINSONS DISEASE |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 120MG/10ML;2400MG/10ML (12MG/ML;240MG/ML) | VYALEV | ABBVIE | N216962 | Oct. 16, 2024 | RX | SOLUTION | SUBCUTANEOUS | Oct. 16, 2027 | NEW PRODUCT |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| CHEMBL4594379 | ChEMBL_ID |
| 13174 | IUPHAR_LIGAND_ID |
| DB16683 | DRUGBANK_ID |
| 1332139005 | SNOMEDCT_US |
| 1332453004 | SNOMEDCT_US |
| 4043479 | VANDF |
| C5238075 | UMLSCUI |
| 11006 | INN_ID |
| 127766 | PUBCHEM_CID |
| 42573 | MMSL |
| d10166 | MMSL |
| 019433 | NDDF |
| D11839 | KEGG_DRUG |
| 37NQZ0J76I | UNII |
| 2695775 | RXNORM |
| 37NQZ0J76I | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vyalev | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-0501 | INJECTION | 240 mg | SUBCUTANEOUS | NDA | 30 sections |